Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 5:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 3,411 matching trials from the live ClinicalTrials.gov search.
Conditions
COVID-19 Pneumonia
Interventions
PF-06650833, Matching Placebo
Drug
Lead sponsor
Giovanni Franchin, M.D, Ph.D
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Intensive Care Unit ICU, Intubation, Critical Illness, Mechanical Ventilation, Pain Measurement, Pain, Procedural, Oxidative Stress, Hypoxia, Biomarkers / Blood, Adult, Uric Acid, Sepsis, COVID, Influenza, Pneumonia
Interventions
endotracheal tube suctioning
Procedure
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Loma Linda, California
Conditions
COVID19, ARDS
Interventions
CK0802, Placebo
Biological · Drug
Lead sponsor
Cellenkos, Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Baltimore, Maryland • New York, New York • Chapel Hill, North Carolina + 2 more
Conditions
Influenza
Interventions
AVX502, Placebo
Biological
Lead sponsor
AlphaVax, Inc.
Industry
Eligibility
65 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Lenexa, Kansas
Conditions
Influenza A H3N2, Influenza A H1N1
Interventions
FLU-IGIV, Placebo for FLU-IGIV
Biological · Other
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 34 more
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Durvalumab, Tremelimumab, Pemetrexed, Pembrolizumab, Carboplatin, Cisplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
47
States / cities
Beverly Hills, California • La Jolla, California • Los Alamitos, California + 40 more
Conditions
COVID19
Interventions
Nitric Oxide Gas, Inhaled Supplemental Oxygen
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Not listed Not applicable Interventional Accepts healthy volunteers

TaiChi-DTx for Treating Long Covid Symptoms

NCT05419219
Conditions
Fatigue, Dyspnea, Cognitive Impairment, Muscle Pain
Interventions
the multi-domain Tai Chi Digital therapy Software Application
Device
Lead sponsor
Tim Shi
Other
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Ellicott City, Maryland
Withdrawn Not applicable Interventional

P-Co-Li (Pulmonary Covid-19 Study)

NCT04782700
Conditions
Covid19, Lung Inflammation, Hypoxemic Respiratory Failure
Interventions
Steroid Taper (Prednisone)
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Manhasset, New York
Conditions
Covid-19, Sars-CoV2
Interventions
Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
Biological
Lead sponsor
Noah Merin
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Los Angeles, California • Baltimore, Maryland
Completed Phase 2 Interventional Accepts healthy volunteers

Trivalent rHA Dose Escalation Study in Elderly Subjects

NCT00170443
Conditions
Influenza
Interventions
rHAO Trivalent Influenza Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
65 Years to 80 Years
Enrollment
399 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2004
U.S. locations
3
States / cities
Rochester, New York • Cincinnati, Ohio • Houston, Texas
Terminated Phase 2Phase 3 Interventional Results available

Evaluation of ADG20 for the Prevention of COVID-19

NCT04859517
Conditions
COVID-19
Interventions
ADG20, Placebo
Drug
Lead sponsor
Invivyd, Inc.
Industry
Eligibility
12 Years and older
Enrollment
2,582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
66
States / cities
Birmingham, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 60 more
Conditions
Covid19, Cancer, Malignancy, Vaccine Response Impaired
Interventions
SARS-COV2 Pfizer Vaccine
Biological
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tucson, Arizona
Completed Phase 1 Interventional Accepts healthy volunteers

MEDI-557 Adult Dosing

NCT01562938
Conditions
Respiratory Syncytial Virus
Interventions
Placebo, MEDI-557
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Miami, Florida
Conditions
Esophageal Cancer, Lung Cancer, Lymphoma
Interventions
topotecan hydrochloride, low-LET electron therapy, low-LET photon therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Madison, Wisconsin
Not listed Not applicable Interventional Accepts healthy volunteers

COVID-19 Breastfeeding Guideline for African-Americans

NCT04476940
Conditions
Covid19, Exclusive Breastfeeding
Interventions
COVID-19 Breastfeeding Support
Behavioral
Lead sponsor
Meharry Medical College
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Long COVID, Long Covid19, Long Covid-19
Interventions
Ivabradine, Ivabradine Placebo, Coordinated Care, Usual Care
Drug · Behavioral
Lead sponsor
Kanecia Obie Zimmerman
Other
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Post-Acute COVID-19 Syndrome
Interventions
osteopathic manipulative treatment (OMT)
Procedure
Lead sponsor
A.T. Still University of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Kirksville, Missouri
Recruiting Phase 1 Interventional Accepts healthy volunteers

A/Texas Flu Challenge

NCT06753474
Conditions
Influenza
Interventions
Influenza Virus influenza A H3N2 strain
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Conditions
COVID-19 Infection
Interventions
Zavegepant (BHV-3500), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Philadelphia, Pennsylvania • Charleston, South Carolina
Conditions
Post-COVID-19 Condition, Post-COVID Condition, Post-COVID Syndrome, Long COVID, Chronic Fatigue, Chronic Fatigue Symptoms, Fatigue Post Viral
Interventions
REGENECYTE®
Biological
Lead sponsor
StemCyte, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
2
States / cities
Miami, Florida • Miami Lakes, Florida
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects

NCT00630331
Conditions
Influenza
Interventions
Cell culture-derived influenza vaccine, Egg-derived influenza virus vaccine, Placebo
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
18 Years to 49 Years
Enrollment
11,404 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
17
States / cities
Denver, Colorado • Pembroke Pines, Florida • South Miami, Florida + 13 more
Conditions
SARS-CoV-2, COVID-19
Interventions
Evusheld
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
5,814 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Salt Lake City, Utah